Histopathologic Patterns of Recurrent Choroidal Melanoma Following I-125 Plaque Brachytherapy.
Choroidal melanoma
I-125 plaque brachytherapy
Immunohistochemistry
Local tumor recurrence
Tumor radioresistance
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
07
09
2018
accepted:
09
04
2019
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
1
2
2020
Statut:
ppublish
Résumé
Histologic correlation of clinical patterns of recurrent choroidal melanoma following I-125 plaque brachytherapy was performed to identify pathologic mechanisms of recurrence. We reviewed 7 cases of recurrent choroidal melanoma following I-125 plaque brachytherapy managed with enucleation. Clinical characteristics included tumor dimensions, radiation dose, time to local recurrence, and clinical pattern of recurrence. Histopathology (hematoxylin and eosin and periodic acid - Schiff) and immunohistochemistry (Ki-67, CD-163, HMB45, and SOX10) were performed. Mean follow-up time and time to local recurrence were 42 and 21 months after brachytherapy, respectively. Tumor recurrences were described clinically as marginal in 43%, diffuse in 29%, and extraocular extension (EOE) in 29%. Eighty-six percent were classified as mixed cell type and 14% were epithelioid type. Tumor zonation (histologic demarcation between zones of recurrent and nonrecurrent tumor cells by immunohistochemistry) was present in marginal and EOE cases ( Our observations provide a correlation between histopathologic and clinical patterns of local recurrence of choroidal melanoma after brachytherapy.
Identifiants
pubmed: 32002406
doi: 10.1159/000500446
pii: oop-0006-0050
pmc: PMC6984146
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50-57Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Am J Ophthalmol. 1998 Jun;125(6):745-66
pubmed: 9645714
Eye (Lond). 2008 May;22(5):701-6
pubmed: 18049486
Arch Ophthalmol. 2008 Feb;126(2):207-12
pubmed: 18268211
PLoS One. 2018 Apr 12;13(4):e0195151
pubmed: 29649284
Ocul Oncol Pathol. 2015 Apr;1(3):141-50
pubmed: 27172424
Am J Ophthalmol. 2017 Apr;176:40-45
pubmed: 28048976
Br J Ophthalmol. 2001 Oct;85(10):1208-12
pubmed: 11567966
Ophthalmology. 1990 Dec;97(12):1665-70
pubmed: 2087297
Am J Ophthalmol. 2000 Feb;129(2):199-204
pubmed: 10682973
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2561-5
pubmed: 12147585
Ophthalmology. 2002 Dec;109(12):2197-206
pubmed: 12466159
Ophthalmology. 1997 Nov;104(11):1785-92; discussion 1792-3
pubmed: 9373108
Br J Ophthalmol. 2017 Jun;101(6):747-751
pubmed: 27574179
Invest Ophthalmol Vis Sci. 2005 May;46(5):1561-4
pubmed: 15851551
Am J Ophthalmol. 2017 May;177:9-16
pubmed: 28163118
Brachytherapy. 2014 Jan-Feb;13(1):1-14
pubmed: 24373763